CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pell Bio Med Technology Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pell Bio Med Technology Co Ltd
4F
NO.87, Xinhu 2nd Road, Neihu District
Phone: +886 287911789p:+886 287911789 TAIPEI, 114  Taiwan Ticker: 69496949
Business Summary
Pell Bio Med Technology Co Ltd is a Taiwan-based trading company mainly engaged in the immune genetic engineering and the development of non-genetically modified cell therapy products and non-cell products. The main business focuses on immune cell therapy that uses genetic engineering to modify the patient's own immune cells. The Company is engaged in the development of chimeric antigen receptor T cell therapy for the treatment of B-cell lymphoma PL001. Non-genetically modified cell therapy products include cytokine-induced killer cells (CIK), and mixed cells using a combination of dendritic cells and cytokine-induced killer cells (DC-CIK). Non-cell products include hair care products and others.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Head of Finance & Accounting, Corporate Governance Officer ChangminWu 8/13/2024 7/12/2024
Director JianchengGuo 11/8/2024 11/8/2024

General Information
Outstanding Shares: 57,712,550 (As of 9/23/2024)
Shareholders: 404
Stock Exchange: TPE
Fax Number: +886 287911795


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024